Skip to main content
OpenTrials
Completed

NCT Number: NCT01712594

Safety and Effectiveness Study of a Closed Loop System Maintaining Patients' Glucose Levels During an Overnight Period

Currently, patients diagnosed with type 1 diabetes rely on either finger stick or sensor glucose readings when making their insulin dosage decisions. Designing a computerized system that mimics the way insulin is produced naturally in a person who does not have type 1 diabetes holds many challenges; all of which cannot be addressed in just one study. The purpose of the Medtronic Overnight Closed Loop study is to assess the performance of a system designed to automatically infuse the correct insulin dose during the hours that the patient is sleeping.

The system consists of an insulin pump that provides insulin to the patient through an infusion set. A sensor inserted just under the patient's skin measures glucose levels and a transmitter sends this information to the pump. To enable the sensor to register the glucose information correctly, it must be set (calibrated) by a finger stick blood glucose 3-4 times a day. In the commercially released system, the physician would recommend the continuous background (basal) insulin rates and the patient would be required to make decisions regarding extra insulin (bolus) for meals or as a response to high glucose levels.

In the Closed Loop System, a mobile control system is added to these devices. This consists of an Android phone, a closed loop algorithm and a translator. This system is designed to translate the sensor information and direct the pump to provide the required dosage of insulin automatically without requiring input from the patient.

Reliable calibration has proved challenging, and so it is important that the system function safely, even when calibration is inaccurate. In this study, a calibration error will be introduced under very controlled circumstances. This testing will identify if the system can maintain acceptable overnight glucose levels, regardless of whether or not calibration is ideal.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 1 Diabetes Autoimmune Diseases Diabetes Mellitus Diabetes Mellitus, Type 1 Endocrine System Diseases Glucose Metabolism Disorders Immune System Diseases Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

King's College London

London, SE5 9PJ, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A clinical diagnosis of Type 1 diabetes as determined by the Investigator for a minimum of 36 months prior to enrollment
  • Weight is between 50 and 120 kg
  • Subject has used a Medtronic insulin pump for at least the previous 6 months
  • Subject has an glycated hemoglobin (A1C) value ≤ 9.0% demonstrated at the time of enrollment
  • Subject uses a rapid-acting analogue insulin in his/her pump

Exclusion criteria

  • Female subject who has a positive serum pregnancy screening test, or who plans to become pregnant during the course of the study
  • Subject has a history of hypoglycemic seizure or hypoglycemic coma within the past 12 months
  • Subject has an exclusionary cardiac disorder

Treatment and study plan

Closed Loop Procedure (Medtronic)

Device

The procedure A is the device running under normal conditions, procedure B will incorporate an induced calibration error.

Other names: AAGC

Primary outcomes

  1. Amount of time spent in the target range defined as 3.8-8.8 mmol/l (70 to 160 mg/dL) YSI glucose during in-clinic overnight visits

    Time frame: Two in-patient nights

    Subjects will arrive at the research facility between 17:00 and 18:00. Plasma glucose will be measured and they will have their evening meal of no more than 80 g of carbohydrate. They will bolus for this meal using their usual Bolus Wizard (Medtronic) settings. After the meal, an IV catheter will be inserted for the collection of venous blood samples. The Mobile Control System will be connected and closed-loop control will be started approximately 4 hours after dinner. The subject will remain under closed-loop control overnight (approximately 11 p.m.-6 a.m.). During one of the Closed Loop nights the system will be challenged by a calibration error of 30%. At approximately 7 am (before breakfast), the Mobile Control System will be turned off and the patient will be provided with a breakfast (approximately 40-70 gm of carbohydrate) and will take a bolus according to the Bolus Wizard. The patient will return to their usual pump treatment with the MiniMed Paradigm Veo System.

Secondary outcomes

  1. Glucose Area under the curve (AUC) below 3.8 mmol/l (70 mg/dL ) YSI glucose obtained during in-clinic overnight visits

    Time frame: Two overnight closed loop sessions

    Blood glucose samples will be obtained from the line approximately every 30 minutes, or every 5-15 minutes at treating physician's discretion, if either the sensor or a previous glucose reading is < 81mg/dL or > 360mg/dL (< 3.5 mmol/l or > 20 mmol/l). Plasma samples will be analyzed using a YSI 2300 Glucose and Lactate Analyzer between 18:00 and 6:00.

  2. Glucose AUC above 8.8mmol/l (160 mg/dL) YSI glucose obtained during in-clinic overnight visits

    Time frame: Two overnight closed loop sessions

    Blood glucose samples will be obtained from the line approximately every 30 minutes, or every 5-15 minutes at treating physician's discretion, if either the sensor or a previous glucose reading is < 81mg/dL or > 360mg/dL (< 3.5 mmol/l or > 20 mmol/l). Plasma samples will be analyzed using a YSI 2300 Glucose and Lactate Analyzer (YSI, Inc., OH, USA) between 18:00 and 6:00.

Other outcomes

  1. All descriptive endpoints stratified by the accuracy of the sensor based on mean absolute relative difference (MARD) overnight

    Time frame: Two overnight closed loop sessions

    A meter blood glucose (BG) value is entered into the Android and a sensor and calibration error check are performed. If the routine determines that the sensor and BG are valid values, the Closed Loop will start.

Sponsors and collaborators

Lead sponsor

Medtronic MiniMed, Inc.

Industry

Registry information

Official study title

Feasibility and Safety of a Closed Loop Insulin Delivery System (Aka AAGC) With an Artificially Induced Calibration Error During the Overnight Period

Important dates

Study start
2013
Primary completion
2013
Study completion
2014
First posted
Oct 23, 2012
Registry last updated
May 12, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.